Just like the novel coronavirus itself, the emergence of so-called long COVID has surprised both the patients who couldn’t shake their symptoms and the clinicians who have struggled to provide effective treatments. Now, as the U.S. looks to move past the pandemic, there remain unanswered questions about how this fallout from the virus might hamper some workers and for how long. These uncertainties could have important implications for workers’ compensation. By some measures, one in four patients who get COVID-19—even those with mild or asymptomatic cases—will experience subsequent symptoms that range from muscle and nerve pain to breathing difficulties to anxiety and depression. The scope of the challenge will require providers and employers to better understand the nature of the conditions, their origins, and the best paths for treatment. Watch this on-demand webinar to learn more about long COVID and the implications for workers and employers.
More stories
A Breakthrough in Pain Management: Inside the Promise of Journavx
Enlyte’s Nikki Wilson offers a fresh take on a promising alternative to opioids, a first-of-its-kind FDA-approved non-addictive medication for pain.
Resilience Redefines Results
Join our upcoming webinar to discover how resilience can be a game-changer in driving better outcomes for injured employees. From accelerating recovery to improving return-to-work success, resilience plays a critical role in both mental and physical well-being.
Practical Application of Behavioral Coaching Techniques
This case study showcases the power of behavioral coaching techniques in transforming an injured employee’s recovery. Through empathy, active listening, and strategic intervention, Enlyte’s Telephonic Case Manager helped break barriers to healing—leading to improved outcomes, renewed engagement and meaningful cost savings.
From Setback to Comeback: Effective Solutions for Delayed Recovery
Learn how to effectively ignite workers' compensation recovery by addressing some of the biggest return-to-work obstacles, including mental health comorbidities, social factors, and delayed intervention. See how data-driven strategies lead to successful claims management and faster employee recovery.
Pulsing Recovery: Bone Growth Stimulation's Impact on Comp
Discover how bone growth stimulators are accelerating recovery in workers’ comp. Nicole Usher joins the Enlyte Envision podcast to discuss how BGS devices support healing in complex fractures and spinal surgeries.
Ask The Pharmacist: FDA Approval of Non-Opioid Medication for Acute Pain
The U.S. Food and Drug Administration (FDA) recently approved Journavx (suzetrigine), a novel non-opioid medication developed by Vertex Pharmaceuticals for the treatment of moderate to severe acute pain in adults. This approval, announced on January 30, 2025, marks a significant milestone in pain management, introducing the first new class of oral medication for acute pain in over two decades.